REDWOOD CITY, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced the Company will be participating in two upcoming investor conferences.
Avinger's management is scheduled to present at the Stephens Fall Investment Conference in New York City, NY on Tuesday, November 10, 2015 at 10:00am ET.
Avinger's management is also scheduled to present at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York, NY on Thursday, November 19, 2015 at 11:30am ET.
Interested parties can access the live audio webcast with accompanying slides for both of these presentations on the Events section of Avinger's website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The Company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger's current lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit the Company's website at www.avinger.com.
CONTACT: INVESTOR CONTACT Leigh Salvo (415) 513-1281 Email: email@example.com